Table 1 Baseline patient characteristics—safety population (N = 23)

Age (Years)

Mean ± SD

61.9 ± 13.75

62.5 ± 8.91

62.3 ± 10.52

Median (range)

62.5 (35, 84)

63.0 (44, 77)

63.0 (35, 84)

Gender, n (%)

Female

4 (50)

4 (27)

8 (35)

Male

4 (50)

11 (73)

15 (65)

Race, n (%)

White

6 (75

9 (60)

15 (65)

Black or African American

2 (25)

4 (27)

6 (26)

Latino

0

1 (7)

1 (4)

Other

0

1 (7)

1 (4)

ECOG Performance Status, n (%)

0

3 (38)

6 (40)

9 (39)

1

5 (63)

7 (47)

12 (52)

2

0

2 (13)

2 (9)

PTCL Subtype,

n (%)

ALCL, ALK-negative

1 (13)

0

1 (4)

ALCL, ALK-positive

1 (13)

1 (7)

2 (9)

Angioimmunoblastic TCL

1 (13)

9 (60)

10 (43)

Cytotoxic T-cell phenotype

0

1 (7)

1 (4)

PTCL NOS

5 (63)

4 (27)

9 (39)

Disease Stage, n (%)

IIB

0

2 (13)

2 (9)

IIIA

3 (38)

2 (13)

5 (22)

IIIB

0

2 (13)

2 (9)

IVA

1 (13)

5 (33)

6 (26)

IV B

4 (50)

4 (27)

8 (35)

International Prognostic Index

0—Low Risk

0 (0)

1 (7)

1 (4)

1—Low-Intermediate Risk

3 (38)

3 (20)

6 (26)

2—High-Intermediate Risk

4 (50)

7 (47)

11 (48)

3—High Risk

1 (13)

4 (27)

5 (22)